Computational models in inflammatory bowel disease

Area of Science:

• Computational biology
• Systems biology
• Medical informatics

Background:

• Inflammatory bowel disease (IBD) is a chronic condition with limited treatment efficacy (40%-60%) and significant heterogeneity.
• Current IBD treatment relies on clinical features, lacking specific biomarkers for predicting therapeutic response.
• The exponential growth of omics and pathogenesis data makes IBD suitable for AI-driven discovery.

Purpose of the Study:

• To explore multiscale hybrid models for predicting therapy response in IBD.
• To investigate the role of artificial intelligence (AI) in understanding IBD and improving clinical outcomes.
• To leverage digital twins for precision dosing and tailored IBD treatments.

Main Methods:

• Review of multiscale hybrid models combining mechanistic approaches and machine learning.
• Application of AI for analyzing IBD data (omics, pathogenesis).
• Modeling of Interleukin-6 (IL-6) biology to predict treatment response.

Main Results:

• AI and multiscale models offer potential for enhanced IBD treatment strategies.
• Digital twins can be created for individual patients to enable precision medicine.
• Modeling IL-6 biology improves the predictive accuracy of therapeutic responses in IBD.

Conclusions:

• Multiscale models and AI are crucial for advancing precision medicine in IBD.
• Digital twins generated through these models promise tailored treatments and improved patient outcomes.
• Accurate modeling of key biological pathways, like IL-6 signaling, is essential for reliable treatment prediction in IBD.